In Vivo Genome‑Editing Therapy for Duchenne Muscular Dystrophy
Published: 14 October 2026| Version 1 | DOI: 10.17632/pfr7vfj8w7.1
Contributor:
Guoling LiDescription
Related to Figure 2E: Dystrophin protein levels in indicated tissues at 6 months post-treatment, quantified by immunoblot and expressed as a percentage of wild-type (WT) levels Related to Supplementary Figure S1D: Western blot confirming the absence of dystrophin in indicated muscle tissues Related to Supplementary Figure S2E:Western blot analysis of dystrophin and vinculin expression in TA muscles 6 weeks after injection with AAVs or saline. Related to Supplementary Figure 5E:Western blot analysis of dystrophin and vinculin expression in patients baseline and D90.
Files
Categories
Western Blot